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Abstract
Objective: To evaluate cost-utility of infliximab and adalimumab for the treatment of moderate-
to-severe ulcerative colitis (UC) refractory to conventional therapies in Canada.
Methods: A Markov model was constructed to evaluate incremental cost-utility ratios (ICUR) of
5 mg/kg and 10 mg/kg infliximab and adalimumab therapies compared to 'usual care' in treating a
hypothetical cohort of patients (aged 40 years and weighing 80 kg) over a five-year time horizon
from the perspective of a publicly-funded health care system. Clinical parameters were derived
from the Active Ulcerative Colitis Trials 1 and 2. Costs were obtained through provincial drug
benefit plans. ICUR was the main outcome measure and both deterministic and probabilistic
sensitivity analyses were conducted.
Results: Compared to the strategy A ('usual care') in the base case analysis, the ICURs were
CA$358,088/QALY for the strategy B ('5 mg/kg infliximab + adalimumab') and CA$575,540/QALY
for the strategy C ('5 mg/kg and 10 mg/kg infliximab + adalimumab'). The results were sensitive to:
the remission rates maintained in responders to 'usual care' and to 5 mg/kg infliximab, the rate of
remission induced by adalimumab in non-responders to 5 mg/kg infliximab, early surgery rate, and
utility values. When the willingness to pay (WTP) was less than CA$150,000/QALY, the probability
of 'usual care' being the optimal strategy was 1.0. The probability of strategy B being optimal was
0.5 when the WTP approximated CA$400,000/QALY.
Conclusions: The ICURs of anti-TNF-α drugs were not satisfactory in treating patients with
moderate-to-severe refractory UC. Future research could be aimed at the long-term clinical
benefits of these drugs, especially adalimumab for patients intolerant or unresponsive to infliximab
treatment.
Introduction
Ulcerative colitis (UC) is a chronic inflammatory disease
of the gastrointestinal tract of unknown etiology [1]. It is
characterized by diffuse mucosal inflammation limited to
the colon. The most consistent clinical manifestation of
UC is the presence of blood and mucus mixed with stool,
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accompanied by lower abdominal cramping which is
most intense during bowel movements. Patients with
refractory UC present persistent acute symptoms despite
anti-inflammatory therapies or have chronically active
disease requiring continuous treatment and long-term fol-
low-up [2]. Conventional medical management of active
UC includes: 5-aminosalicylates (5-ASA), corticosteroids,
and immunosuppressants [3]. The therapeutic approach
is determined by the severity of the symptoms and the
degree of intestinal involvement. Surgical management
may be necessary in poorly controlled or recurrent UC.
The introduction of novel biological therapies has
changed the therapeutic approach to UC, particularly in
patients with severe and refractory disease. Tumor necro-
sis factor α (TNF-α) is found in increased concentrations
in blood, colonic tissue, and stools of patients with UC
[4]. Infliximab (Remicade®, Schering) and adalimumab
(Humira®, Abbott) are recombinant monoclonal antibod-
ies that bind to human TNF-α, neutralizing its biologic
activity [5-7]. Infliximab has been demonstrated to induce
and maintain clinical response and remission in patients
with moderate-to-severe UC who have not responsed to
conventional therapies [8-12].
Infliximab, since its approval, is increasingly being used in
patients with UC who are refractory to conventional ther-
apies[13]. This treatment strategy aims at improving
symptom control and reducing the need for hospitaliza-
tion and surgery. Adalimumab is recommended for
patients with Crohn's disease not responding to or unable
to tolerate infliximab[14] due to its potential advantages
over infliximab in terms of elimination of infusion reac-
tions and possible reduction in the requirement for dose
escalation over time [15]. However, the evidence on clin-
ical performance of adalimumab over infliximab in UC is
rather limited [16,17].
Despite the clinical benefits, induction and maintenance
therapy using anti-TNF-α drugs is expensive. The esti-
mated patient annual drug costs range from CA$23,000 to
CA$38, 000 [18]. The prevalence of UC in Canada is
193.7 per 100,000 with 11.8 new cases per 100,000 each
year [19]. Assuming 5% of the cases have moderate-to-
severe refractory UC [20], approximately 8,500 patients
will require treatment with an anti-TNF-α drug in Canada.
Consequently, the volume of reimbursement requests, to
the publicly funded drug plans in Canada, for infliximab
and adalimumab from patients with refractory UC is
increasing. These anti-TNF-α drugs are not listed as a gen-
eral benefit in several provinces therefore reimbursement
may be based on pre-set criteria or case-by-case reviews.
There is a need in these jurisdictions for improving this
process and developing reimbursement criteria or updat-
ing existing criteria. Therefore, this study was to evaluate
the cost-utility of infliximab and adalimumab for the
treatment of moderate-to-severe UC refractory to conven-
tional therapies in Canada.
Methods
Study design
This was an economic evaluation of different medical
management strategies for moderate-to-severe refractory
UC from the perspective of a publicly funded healthcare
system over a five-year time horizon. The relatively short
time horizon was selected due to the lack of long-term
clinical evidence of these drugs in UC. The target popula-
tion was a hypothetical cohort of patients (aged 40 years
and weighing 80 kg) with moderate-to-severe active
refractory UC.
Management strategies to be compared
The management strategies included (A) 'usual care': con-
ventional medical treatment without anti-TNF-α drugs,
the medications selected depended on the health states
according to the inputs of two practicing gastroenterolo-
gists from tertiary care hospitals in two large urban regions
within Ontario. There are four 5-ASA drugs commonly
used for therapy in IBD. They suggested the proportion of
patients utilizing each of the four 5-ASA drugs and the
three immunosuppressant drugs based upon their own
experiences (Table 1); (B) '5 mg/kg infliximab + adalimu-
mab' initial and maintenance therapy using 5 mg/kg inf-
liximab and then switch to adalimumab if there is no
Table 1: Profiles of concomitant medications and costs (2008 CA$)
Health state Medications Proportion Daily dose Drug costs per 12 weeks Total costs of health state
Remission None - - - $0.00
Active UC
Responsive 5-ASA 0.9 4 g $348.83 $698.44
mesalamine enema 1.0 4 g $384.50
Nonresponsive 5-ASA 0.9 4 g $348.83 $786.55
mesalamine enema 1.0 4 g $384.50
azathiopirne/6 MP* 0.4 150/75 mg $222.76
5-ASA: 5-aminosalicylates with an assumption of a 45:25:15:15 split of Pentasa:Asacol: salofalk:sulfasalazine.
*assumes 70:30 split of azathioprine:6 MP.Cost Effectiveness and Resource Allocation 2009, 7:20 http://www.resource-allocation.com/content/7/1/20
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response to the initial therapy or response is lost during
maintenance therapy; (C) '5 mg/kg and 10 mg/kg inflixi-
mab + adalimumab': initial therapy using 5 mg/kg inflix-
imab, if there is no response, dose escalated to 10 mg/kg
infliximab, and if response is lost during maintenance
therapy, switch to adalimumab. Details on strategy B and
C are shown in Figure 1.
Markov model
A five-health state Markov model was constructed to com-
pare the incremental cost-utility of these three manage-
ment strategies. The Active Ulcerative Colitis Trials 1 and
2 (ACT 1 and ACT 2) were the main sources of the clinical
parameters used in the model[10]. The length of a Markov
cycle was determined by the treatment intervals adopted
in the ACTstudies.
Specifically, the first cycle was from week 0 to week 8, the
second from week 9 to week 30, the third from week 31 to
week 54, and then every 27 weeks for each cycle starting
from week 55. Remission was defined as a total Mayo
score of 2 points or lower, without individual sub-scores
exceeding 1 point[10]. As the definitions of remission and
response were overlapping in the ACT studies[10],
responders defined in the present study excluded those
achieving remission in order to make these two states
mutually exclusive. The state of active UC consisted of
both responders and non-responders to anti-TNF-α drugs.
For those patients with remission after the initial therapy,
they might lose response and thus move to active UC
state, or stay in the remission state over time. For those
responders in active UC, they might achieve remission or
stay in the active UC state with the maintenance therapy.
For those non-responders in the active UC state, a propor-
tion of them underwent total colectomy with a one-stage
ileal-pouch anal anastomosis (IPAA)[21] and the remain-
ing either switched to adalimumab (as in strategy B) or
increased the dose of infliximab (as in strategy C). The
patients who experienced complications either achieved
remission due to successful treatments for the complica-
tions (either medical or surgical), or still suffered compli-
cations despite the treatments. Those who achieved
surgical remission might either develop complications
later or stay in the remission state. Mortality was not con-
sidered due to the short time horizon. As the mortality
rate is assumed the same for all strategies, impact of
excluding mortality in the present evaluation would be
minimal. A simplified schematic is displayed in Figure 2.
Clinical parameters
Clinical parameters were estimated using a fixed-effect
meta-analysis of the findings from the ACT studies[10].
Treatment strategies Figure 1
Treatment strategies.
Strategy A  Strategy B  Strategy C 
Usual care  5 mg/kg infliximab 
(week 0, 2 and 6) 
Response
5/10 mg/kg infliximab 
(every 8 week) 
Yes No
10 mg/kg infliximab 
(every 8 week) 
Response
5 mg/kg infliximab 
(every 8 week) 
Adalimumab  
160 mg at week 0 
80 mg at week 2 
40 mg weekly 
starting from week 4 
Yes No
Response
5 mg/kg infliximab 
(every 8 week) 
Surgery
No
Surgery
Response
5 mg/kg infliximab 
(every 8 week) 
Yes No
Adalimumab  
160 mg at week 0 
80 mg at week 2 
40 mg weekly 
starting from week 4 
Yes
5 mg/kg infliximab 
(week 0, 2 and 6) Cost Effectiveness and Resource Allocation 2009, 7:20 http://www.resource-allocation.com/content/7/1/20
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The remission rates among responders and non-respond-
ers by treatment options are listed in Table 2. The clinical
parameters for 'usual care' (strategy A) were estimated
using those observed in the placebo arm of the ACT stud-
ies where some concurrent treatment with conventional
drugs was allowed [10]. However, resource utilization and
costs for the 'usual care' were based on the inputs from
local clinicians to reflect the disease management process
in Canada. A proportion of non-responders to medical
treatment underwent surgery. The rate of surgery, within
one year after the initial therapy, was 0.291 [8], while the
rate of late surgery [i.e., beyond one year] was 0.087[22].
According to a large study by Fazio et al[23], the compli-
cation rate, within 30 days after the surgery, was 0.274
and the later complication rate (> 30 days) was 0.507. The
overall success rate for the treatment of complications was
0.84[24]. These rates were not varied across treatment
strategies. Table 3 shows time-dependent clinical parame-
ters used in the model, including remission rate for each
of the treatment options, the rates of maintaining remis-
sion over time and the proportion of non-responders in
those with active UC. All these parameters were directly
derived from the ACT studies[10]. To date only two small
studies reported that adalimumab offered clinical benefits
to a subgroup of patients (40% to 60%) that had a loss of
response or were intolerant to infliximab[16,17]. Based
on these findings, a conservative assumption was made
that remission and response rates of maintenance therapy
using adalimumab were equivalent to that of 5 mg/kg inf-
liximab. The remission rate induced by adalimumab
Simplified Markov model schematic Figure 2
Simplified Markov model schematic.
Table 2: Time-independent parameters used in the model
Point estimate SE Distribution Ref.
Remission rates in responders
Usual care 0.146 0.047 Beta (α = 8.11; β = 47.34) (10)
5 mg/kg infliximab 0.276 0.052 Beta (α = 20.20; β = 52.95) (10)
10 mg/kg infliximab 0.255 0.047 Beta (α = 21.71; β = 63.44) (10)
Adalimumab 0.276 0.052 Beta (α = 20.20; β = 52.95)
Remission rates in
non-responders
Usual care 0.063 0.019 Beta (α = 10.17; β = 152.17) (10)
10 mg/kg infliximab 0.078 0.029 Beta (α = 6.54; β = 76.96) (10)
Adalimumab 0.100 0.020 Beta (α = 22.40; β = 201.60) (16)
Probabilities
Early IPAA 0.291 0.093 Beta (α = 6.71; β = 16.29) (8)
Late IPAA 0.087 0.010 Beta (α = 66.99; β = 703.01) (22)
Early complications 0.274 0.014 Beta (α = 275.65; β = 728.83) (23)
Late complications 0.507 0.016 Beta (α = 527.02; β = 512.01) (23)
Successful treatment for complications 0.840 0.031 Beta (α = 117.60; β = 22.40) (24)
Costs (2008CA$)
Infliximab, 100 mg/vial 952 50 Gamma(α = 362.44; β = 2.63) (25,26)
Adalimumab, 400 mg 715 46 Gamma(α = 237.56; β = 2.98) (25,26)
Medical examination 77 (27)
IPAA 12,738 2548 Gamma(α = 25.00; β = 509.52) (28)
Surgical complications 9304 2301 Gamma(α = 16.35; β = 569.08) (28)
Utilities
Remission 0.79 0.035 Beta (α = 108.43; β = 28.82) (21)
Active UC 0.32 0.045 Beta (α = 34.46; β = 73.23) (21)
Surgical remission 0.68 0.042 Beta (α = 83.77; β = 39.42) (21)
Surgical complications 0.49 0.046 Beta (α = 56.91; β = 59.23) (21)
SE: standard error; IPAA: one-stage ileal-pouch anal anastomosis; UC: ulcerative colitis.Cost Effectiveness and Resource Allocation 2009, 7:20 http://www.resource-allocation.com/content/7/1/20
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among those with no response or lost response to inflixi-
mab was 0.1 [16].
Costs and utilities
The cost of infliximab was $952 per 100 mg/vial and the
cost of adalimumab was $715 per 40 mg according to the
provincial drug benefit lists[25,26]. An 8% markup fee
was added to the drug costs. Total costs of medical exam-
ination including chest x-ray, tuberculosis skin test, and
hepatitis B blood test were estimated at $77 according to
the Ontario Schedule of Benefits[27]. Cost of IPAA was
estimated at $12,738 [28]. All costs were reported in 2008
Canadian dollars. Utilities for the four Markov health
states (surgery was a temporary transition state only) were
obtained from the study by Arseneau et al[21] (Table 2).
Both costs and quality-adjusted life years (QALYs) were
discounted at 5% annually in the base case analysis, while
0% and 3% were used in sensitivity analysis.
Outcomes
The primary outcome measure was the incremental cost-
utility ratio (ICUR) between the strategies with 'usual care'
as a reference group.
Base case and sensitivity analyses
The base case analysis estimated the ICURs between the
strategies using point estimates of the parameters (i.e.,
weighted-average from the meta-analysis). One-way
deterministic sensitivity analyses (DSA) were performed
using the lower and upper bounds of the 95% confidence
interval of the parameters that were assumed constant
over time. Probabilistic sensitivity analysis (PSA) was con-
ducted using Monte Carlo simulations. Beta distributions
(generating values bounded between 0 and 1) were fitted
for the clinical parameters and utilities, while gamma dis-
tributions (generating positive values) were fitted for the
cost parameters. Cost-effectiveness acceptability curves
(CEACs) were constructed to show the varying probabili-
ties of being the optimal strategy at different willingness
to pay (WTP) threshold values.
Results
In the base case analysis, strategy A ('usual care') cost
$24,268 and yielded 2.015 QALYs for a patient over a 5-
year period. The corresponding numbers were $82,756
and 2.178 QALYs for strategy B ('5 mg/kg infliximab +
adalimumab') and $101,272 and 2.149 QALYs for strat-
egy C ('5 mg/kg and 10 mg/kg infliximab + adalimu-
mab'). The ICUR was $358,088/QALY for strategy B
versus 'usual care' and $575,540/QALY for strategy C ver-
sus usual care. Strategy C was dominated by strategy B
(Table 4).
The ICURs did not vary greatly when using 0% and 3%
discount rates. Those parameters showing a significant
impact on the ICURs in a one-way DSA are displayed in
Table 4. The ICURs were sensitive to the remission rates
maintained by 'usual care' and 5 mg/kg infliximab, and
also sensitive to the rate of remission induced by adalimu-
mab in non-responders to infliximab. Early IPAA rate and
utility values had a significant impact on the ICURs, while
the impacts from the remaining parameters were negligi-
ble.
CEACs are shown in Figure 3. When the WTP was less
than $150,000/QALY, the probability of 'usual care' being
Table 3: Time-dependent parameters used in the model*
Point estimate (standard error)
Time Usual care 5 mg/kg infliximab 10 mg/kg infliximab Adalimumab
Week 0-8
Remission rate 0.084(0.017) 0.363(0.031) 0.297(0.029) 0.363(0.031)
% Non-responders among patients with active UC 74.4(2.9) 51.9(4.0) 49.4(3.8) 51.9(4.0)
Week 9-30
Maintaining remission rate 0.520(0.099) 0.524(0.053) 0.820(0.045) 0.524(0.053)
% Non-responders among patients with active UC 83.0(2.6) 71.8(3.5) 71.3(3.6) 71.8(3.5)
Week 31-54
Maintaining remission rate 0.799(0.127) 0.856(0.066) 0.781(0.073) 0.856(0.066)
% Non-responders among patients with active UC 96.0(1.9) 83.5(4.2) 85.0(4.0) 83.5(4.2)
Week>54
Maintaining remission rate 0.799(0.127) 0.856(0.066) 0.781(0.073) 0.856(0.066)
% Non-responders among patients with active UC 96.0(1.9) 83.5(4.2) 85.0(4.0) 83.5(4.2)
Active UC refers to active ulcerative colitis that consists of both responders and non-responders.
*The parameters were derived from the study by Rutgeerts et al.[10].Cost Effectiveness and Resource Allocation 2009, 7:20 http://www.resource-allocation.com/content/7/1/20
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the optimal strategy was 1.0. The probability of strategy B
being optimal was 0.5 when the WTP approximated
$400,000/QALY. The probability of strategy C being opti-
mal was very low despite the wide range of WTP values.
Discussion
Increasing health care costs with limited resources is high-
lighting the importance of economic issues in addition to
efficacy and safety. In Canada, economic evaluation has
been incorporated into the decision making process since
1994. Facing increasing volume of reimbursement
requests for anti-TNF-α drugs, the Canadian decision
makers have to evaluate these drugs in terms of incremen-
tal cost-utility over the existing treatment options.
Infliximab has demonstrated clinical efficacy in patients
with active UC in randomized clinical trials[10,16]. How-
ever, the costs of infliximab were significantly higher than
the costs of 'usual care'. The ICUR was not favorable to inf-
liximab based on the existing evidence, according to com-
monly accepted willingness to pay threshold (e.g., US
$50,000).
This study demonstrated that increasing the dose of inflix-
imab to 10 mg/kg in those patients who had a loss of
response to 5 mg/kg infliximab was not cost-effective
compared to either 'usual care' or switching to adalimu-
mab. Clinical experts also suggested a strategy of reducing
the dose interval for non-responders. However, this strat-
egy was not considered in the model due to lack of clinical
evidence.
Adalimumab also induced remission among a certain
proportion of the patients intolerant or unresponsive to
infliximab therapy[16,17]. The performance of adalimu-
mab in those without a response to infliximab has not
been extensively studied to date. Only two small studies
from the same research group have been pub-
lished[16,17]. The long-term performance of adalimu-
mab remains unclear. A large randomized controlled trial
is necessary to address this concern. Nevertheless, the use
of infliximab and adalimumab in patients who are refrac-
tory to conventional therapies might be clinically indi-
cated, while the economic burden of these treatments
should be taken into consideration.
Also, there is a paucity of economic evidence on anti-TNF-
α drugs in treating refractory active UC. A recently pub-
lished economic evaluation of infliximab in the UK
reported an ICUR of £27,424 if adopting a responder
strategy (i.e., continuing 5 mg/kg infliximab in responders
only), while the ICUR was £19,696 for the remission strat-
egy (i.e., continuing 5 mg/kg infliximab in patients
achieving remission only), compared to 'usual care' com-
prising immunomodulators or corticosteroids[29]. These
ICURs were significantly lower than those in the present
study. Although using the same data source (i.e., ACT
studies), the two studies were less comparable in terms of
model structure, model assumption, and management
strategies. Specifically, the UK model had a state for tem-
porary discontinuers. The target population in the UK
study was the patients with moderate-to-severe UC, while
our population was those with similar severity but refrac-
Table 4: Base case and one-way deterministic sensitivity analyses
ΔCosts ΔQALYs ICURs, $/QALY
Values B vs A C vs A B vs A C vs A B vs A C vs A
Base case $58,488 $77,004 $0.163 $0.134 $358,088 $575,540
Remission rate in responders
Usual care 0.054 $58,049 $76,557 0.181 0.151 $320,893 $505,803
0.238 $58,937 $77,446 0.146 0.117 $402,860 $663,307
5 mg/kg infliximab 0.174 $57,360 $76,880 0.121 0.100 $476,059 $768,537
0.378 $59,592 $77,143 0.203 0.166 $293,330 $464,724
Remission rate in non-responders induced
Adalimumab 0.061 $58,054 $76,876 0.123 0.120 $471,182 $641,097
0.139 $58,923 $77,133 0.200 0.146 $295,032 $526,848
Early IPAA 0.108 $72,853 $95,814 0.254 0.215 $286,943 $446,029
0.475 $47,476 $61,931 0.104 0.082 $457,710 $753,220
Utilities
Remission 0.720 $58,499 $77,007 0.111 0.087 $527,236 $889,227
0.858 $58,499 $77,007 0.214 0.180 $273,081 $428,676
Surgical remission 0.598 $58,499 $77,007 0.197 0.167 $296,939 $462,473
0.762 $58,499 $77,007 0.130 0.101 $451,163 $761,873
Surgical complications 0.399 $58,499 $77,007 0.185 0.155 $316,155 $497,122
0.580 $58,499 $77,007 0.142 0.113 $412,327 $681,998
Strategy A: 'usual care'; Strategy B: '5 mg/kg infliximab +adalimumab'; Strategy C: '5 mg/kg and 10 mg/kg infliximab + adalimumab'. IPAA: one-stage 
ileal-pouch anal anastomosis; UC: ulcerative colitis.Cost Effectiveness and Resource Allocation 2009, 7:20 http://www.resource-allocation.com/content/7/1/20
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tory to conventional treatment. In the UK study patients
that did not respond to infliximab were allowed to switch
back to conventional treatment.
The present model did not incorporate adverse events as
the ACT studies reported that the proportions of patients
with any adverse event were similar among the three treat-
ment groups. Nevertheless, the ICUR would be slightly
favorable to 'usual care' if adverse events were included in
the model. For example, the numbers of serious infections
(i.e. lupus-like reactions and neurologic diseases) were
slightly higher among patients treated with infliximab in
the ACT studies. Incorporating these infections into the
model would increase costs and decrease health benefits
in terms of utility for the treatment strategies using inflix-
imab. The present model was also limited by not incorpo-
rating subsequent post surgery treatment strategies. This is
mainly because these treatments are individualized and
thus hard to estimate in a cohort model. This could be a
clinical research priority in the future.
This economic evaluation revealed that the ICURs of anti-
TNF-α drugs were not satisfactory in treating patients with
moderate-to-severe refractory UC in a relatively short
treatment period. Future research could be aimed at the
long-term clinical benefits of these drugs, especially adal-
imumab for patients intolerant or unresponsive to inflixi-
mab treatment.
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